Search - tctmd.com

Displaying 1 - 20 of 109

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

L.A. McKeown

June 18, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

December 2025 Dispatch for the CV Team

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Evolocumab Wins for Primary Prevention in VESALIUS-CV

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Evolocumab Gains Expanded Indication for Primary Prevention

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

The Biggest News of 2023: TCTMD’s Top 10

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content